quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 21, 2026

Social Security's 2027 Cost-of-Living Adjustment (COLA) May Be Among the Largest in 25 Years -- but There's a Catch

View original at nasdaq.com
Social Security's 2027 Cost-of-Living Adjustment (COLA) May Be Among the Largest in 25 Years -- but There's a Catch Key Points Social Security's annual COLA reveal in October is arguably the most anticipated announcement of the year for program recipients…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • A larger-than-expected COLA in 2027 won't change the fact that a Social Security dollar simply isn't what it used to be

    60% confidence
  • Gas prices in the US have moved up to $3.79/gallon, their highest level since September 2023. The 30% spike over the last month ($2.92/gallon to $3.79/gallon) is the biggest we've seen in the past 30 years.

    60% confidence
  • The purchasing power of Social Security income declined 36% from the start of the 21st century to February 2023

    60% confidence
  • The purchasing power of Social Security income dropped 20% from 2010 to 2024

    60% confidence
  • Social Security benefits will rise by 1.7% in 2027

    60% confidence
  • There's a real possibility of the 2027 COLA being among the largest over the last quarter century

    60% confidence
  • Social Security benefits will increase by 2.8% in 2027

    60% confidence
  • Medicare's Part B premium is rising at a significantly faster pace than Social Security's annual COLA more often than not

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com